Is Survodutide legal or available in the EU?

Survodutide is not authorised as a medicine by the European Medicines Agency (EMA); it is investigational and has no EU marketing authorisation for any use. It is supplied strictly as a research chemical for laboratory use only, not for human consumption. Helica dispatches from within the EU. Sale as a research chemical is not the same as approval as a medicine, and national rules on possession and import vary.

Is survodutide approved by the FDA or EMA?

No. As of 2026 survodutide is not approved by the FDA, the EMA, or any major regulator. It has completed phase 2 trials in obesity and MASH, and a phase 3 programme is ongoing. Material sold outside clinical trials is unregulated and labeled research-use-only, not for human consumption.

How does survodutide differ from semaglutide or tirzepatide?

Semaglutide is a single GLP-1 agonist and tirzepatide is a dual GIP/GLP-1 agonist. Survodutide instead pairs GLP-1 receptor agonism with glucagon-receptor agonism, a combination hypothesised to add energy expenditure and hepatic fat metabolism to appetite suppression — which is also why it has been studied specifically in MASH.

What weight loss did survodutide show in trials?

In a phase 2 dose-finding obesity trial, mean body-weight reduction reached roughly 15% at the highest dose (4.8 mg) by week 46, versus about 3% with placebo. These are clinical-trial results in a defined population using pharmaceutical-grade drug, not guarantees for any individual.

Metabolic

Survodutide

Also known as: BI 456906, BI456906

Investigational once-weekly glucagon/GLP-1 receptor dual agonist (BI 456906) from Boehringer Ingelheim/Zealand Pharma; phase 2 obesity and MASH data. Not approved.

Reviewed by the Helica Labs research team · Last updated August 5, 2026

Buy Survodutide

Overview

Survodutide (development code BI 456906) is an investigational, once-weekly injectable peptide being developed by Boehringer Ingelheim in collaboration with Zealand Pharma. It is a dual agonist that simultaneously activates the glucagon receptor and the GLP-1 (glucagon-like peptide-1) receptor. The GLP-1 component reduces appetite and food intake and enhances glucose-dependent insulin secretion, while the glucagon-receptor component is thought to increase energy expenditure and hepatic fat metabolism — the combination that distinguishes survodutide from single GLP-1 agonists. Its most advanced published data come from two phase 2 trials. In a dose-finding phase 2 obesity trial (Lancet Diabetes & Endocrinology, 2024), mean body-weight reduction reached roughly 15% at the highest dose (4.8 mg) at week 46, versus about 3% with placebo. In a separate 48-week phase 2 trial in MASH (metabolic dysfunction-associated steatohepatitis) with fibrosis (NEJM, 2024), survodutide produced dose-dependent improvement in MASH without worsening of fibrosis in a substantially higher proportion of participants than placebo. A phase 3 programme is ongoing. As of 2026, survodutide is NOT approved by the FDA, the EMA, or any other regulator and remains an investigational compound under clinical study. The European Medicines Agency has not authorised survodutide, and any material supplied outside of clinical trials is an unregulated research chemical for laboratory use only — not pharmaceutical-grade and not for human consumption. The information below summarises published trial evidence and is provided for research reference only; it is not medical advice.

How it works

Survodutide is a single synthetic peptide engineered to activate two receptors involved in metabolic regulation: the glucagon receptor and the GLP-1 receptor. GLP-1 receptor agonism promotes satiety, slows gastric emptying, reduces food intake, and enhances glucose-dependent insulin secretion. Glucagon receptor agonism is proposed to raise energy expenditure and promote hepatic lipid metabolism, which may contribute both to weight loss and to the reductions in liver fat seen in MASH studies. The molecule is designed for once-weekly subcutaneous administration. The relative contribution of each receptor to the clinical effects in humans, and the optimal balance of the two activities, remain active questions under investigation.

Researched effects

Clinical Dose-dependent body-weight reduction in adults with overweight or obesity (up to ~15% at 4.8 mg by week 46 in a phase 2 trial)
Clinical Improvement of MASH (metabolic dysfunction-associated steatohepatitis) without worsening of fibrosis versus placebo in a phase 2 trial
Clinical Reductions in liver fat content in people with MASH
Clinical Improved metabolic parameters associated with GLP-1 receptor agonism (e.g., glycaemic measures)
Preclinical Proposed increase in energy expenditure via glucagon-receptor agonism

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

In Boehringer Ingelheim trials, survodutide is given as a once-weekly subcutaneous injection with stepwise dose escalation to limit gastrointestinal side effects. The phase 2 obesity trial evaluated maintenance doses up to 4.8 mg weekly, and the phase 2 MASH trial used doses of 2.4, 4.8, and 6.0 mg weekly, each reached through a gradual titration schedule. These are investigational protocols; survodutide has no approved label or established clinical dosing for general use.

Community-reported dosing (anecdotal)

ANECDOTAL / RESEARCH-REFERENCE ONLY - not medical advice and not an instruction to dose. Because survodutide is a newer investigational compound and less widely available than some research peptides, no established community consensus protocol has emerged. Any discussion in research-peptide forums typically references the published trial doses (once-weekly, titrated upward) as a frame of reference. These are trial doses used with pharmaceutical-grade drug under medical supervision and cannot be assumed safe in unregulated self-experimentation.

Half-life: Survodutide is dosed once weekly by subcutaneous injection in clinical trials, consistent with a long-acting pharmacokinetic profile. A precise human elimination half-life is not prominently published; dosing is titrated gradually to steady state over several weeks.
Routes: subcutaneous

Safety & side effects

In phase 2 trials, the most common adverse events were gastrointestinal - nausea, vomiting, diarrhoea, and constipation - which were dose-dependent, mostly mild-to-moderate, and concentrated during dose escalation; slower titration reduces them. As with other incretin-based agents, the tolerability profile was broadly similar to GLP-1 receptor agonists. As a glucagon-receptor agonist, effects on blood glucose and heart rate warrant monitoring, and the full long-term safety profile will not be established until phase 3 data are complete and regulatory review is conducted. Long-term safety, cardiovascular outcomes, and the effects of unregulated research-grade material are unknown. Not for use in pregnancy. Research-use-only; not approved for human consumption. This information is for research reference only and is not medical advice.

Research summary

Survodutide's evidence base rests on two published phase 2 trials. In the dose-finding obesity trial (Lancet Diabetes & Endocrinology, 2024; le Roux et al.), 387 adults with overweight or obesity received once-weekly survodutide or placebo; mean body-weight change at week 46 was dose-dependent, reaching about -15% at the 4.8 mg dose versus about -3% with placebo. In the 48-week MASH trial (NEJM, 2024; Sanyal et al.), adults with biopsy-confirmed MASH and fibrosis (F1-F3) received survodutide 2.4, 4.8, or 6.0 mg or placebo; a substantially larger proportion of survodutide-treated participants achieved histologic improvement in MASH without worsening of fibrosis than with placebo, alongside reductions in liver fat. The mechanistic rationale is that adding glucagon-receptor agonism to GLP-1 activity layers increased energy expenditure and hepatic fat metabolism on top of appetite suppression. A phase 3 programme is ongoing, and cardiovascular and long-term outcome data are not yet available. The central honest caveat is regulatory status: survodutide is investigational and unapproved everywhere as of 2026. All trial data come from industry-sponsored studies using pharmaceutical-grade drug under medical supervision - conditions that cannot be reproduced with unregulated research-chemical material. This entry summarises published evidence for research reference only and is not a claim of safety or efficacy for any individual.

FAQ

Is Survodutide legal or available in the EU?: Survodutide is not authorised as a medicine by the European Medicines Agency (EMA); it is investigational and has no EU marketing authorisation for any use. It is supplied strictly as a research chemical for laboratory use only, not for human consumption. Helica dispatches from within the EU. Sale as a research chemical is not the same as approval as a medicine, and national rules on possession and import vary.
What is survodutide and who makes it?: Survodutide (development code BI 456906) is an investigational once-weekly injectable peptide developed by Boehringer Ingelheim in collaboration with Zealand Pharma. It is a dual agonist of the glucagon and GLP-1 receptors being studied for obesity and for MASH (a form of fatty liver disease).
Is survodutide approved by the FDA or EMA?: No. As of 2026 survodutide is not approved by the FDA, the EMA, or any major regulator. It has completed phase 2 trials in obesity and MASH, and a phase 3 programme is ongoing. Material sold outside clinical trials is unregulated and labeled research-use-only, not for human consumption.
How does survodutide differ from semaglutide or tirzepatide?: Semaglutide is a single GLP-1 agonist and tirzepatide is a dual GIP/GLP-1 agonist. Survodutide instead pairs GLP-1 receptor agonism with glucagon-receptor agonism, a combination hypothesised to add energy expenditure and hepatic fat metabolism to appetite suppression — which is also why it has been studied specifically in MASH.
What weight loss did survodutide show in trials?: In a phase 2 dose-finding obesity trial, mean body-weight reduction reached roughly 15% at the highest dose (4.8 mg) by week 46, versus about 3% with placebo. These are clinical-trial results in a defined population using pharmaceutical-grade drug, not guarantees for any individual.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.